Results meet target and validate method of treatment.
Phase 3 study met target: significantly prolonged survival rates.
Results of trial consistant with previous results. Final data to be released on April 28 (two weeks).
More than 1,000 patients participated.
Great news for PRR's imunotherapy.
Results meet target and validate method of treatment. Phase 3...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
-0.015(4.23%) |
Mkt cap ! $493.8M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 35.8¢ | 33.5¢ | $1.374M | 3.957M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 95461 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 48512 | 1 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |